Departments of Physiology and Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
Circ Arrhythm Electrophysiol. 2010 Aug;3(4):361-8. doi: 10.1161/CIRCEP.109.931865. Epub 2010 May 21.
Several studies suggest that patients with ischemic cardiomyopathy benefit less from cardiac resynchronization therapy. In a novel animal model of dyssynchronous ischemic cardiomyopathy, we investigated the extent to which the presence of infarction influences the short-term efficacy of cardiac resynchronization therapy.
Experiments were performed in canine hearts with left bundle branch block (LBBB, n=19) and chronic myocardial infarction, created by embolization of the left anterior descending or left circumflex arteries followed by LBBB (LBBB+left anterior descending infarction [LADi; n=11] and LBBB+left circumflex infarction [LCXi; n=7], respectively). Pacing leads were positioned in the right atrium and right ventricle and at 8 sites on the left ventricular (LV) free wall. LV pump function was measured using the conductance catheter technique, and synchrony of electrical activation was measured using epicardial mapping and ECG. Average and maximal improvement in electric resynchronization and LV pump function by right ventricular+LV pacing was similar in the 3 groups; however, the site of optimal electrical and mechanical benefit was LV apical in LBBB hearts, LV midlateral in LBBB+LCXi hearts and LV basal-lateral in LBBB+LADi hearts. The best site of pacing was not the site of latest electrical activation but that providing the largest shortening of the QRS complex. During single-site LV pacing the range of atrioventricular delays yielding > or =70% of maximal hemodynamic effect was approximately 50% smaller in infarcted than noninfarcted LBBB hearts (P<0.05).
Cardiac resynchronization therapy can improve resynchronization and LV pump function to a similar degree in infarcted and noninfarcted hearts. Optimal lead positioning and timing of LV stimulation, however, require more attention in the infarcted hearts.
一些研究表明,缺血性心肌病患者从心脏再同步治疗中获益较少。在一种新的不同步性缺血性心肌病动物模型中,我们研究了梗塞的存在对心脏再同步治疗短期疗效的影响程度。
在左束支传导阻滞(LBBB)伴慢性心肌梗塞的犬心脏中进行实验,通过栓塞左前降支或左回旋支动脉并随后发生 LBBB 来创建模型(LBBB+左前降支梗塞[LADi;n=11]和 LBBB+左回旋支梗塞[LCXi;n=7])。起搏导联放置在右心房和右心室以及左心室(LV)游离壁的 8 个部位。使用心导管技术测量 LV 泵功能,使用心外膜标测和心电图测量电激活同步性。右心室+LV 起搏对电再同步和 LV 泵功能的平均和最大改善在 3 组中相似;然而,最佳电和机械获益的部位在 LBBB 心脏中为 LV 心尖,在 LBBB+LCXi 心脏中为 LV 中侧壁,在 LBBB+LADi 心脏中为 LV 基底外侧。最佳起搏部位不是最晚电激活的部位,而是提供 QRS 复合波最大缩短的部位。在单部位 LV 起搏时,导致 >或=70%最大血液动力学效果的房室延迟范围在梗塞的 LBBB 心脏中比非梗塞的 LBBB 心脏小约 50%(P<0.05)。
心脏再同步治疗可以在梗塞和非梗塞心脏中以相似的程度改善再同步和 LV 泵功能。然而,在梗塞的心脏中,需要更加注意最佳导联定位和 LV 刺激时间。